

CANADIAN GUIDELINES ON SEXUALLY TRANSMITTED INFECTIONS (2008 UPDATE)

VI – SPECIFIC POPULATIONS

PREGNANCY (Updated January 2010)

References

1. Montgomery C, Norman W, Money D, Rekart M. Antibiotic at time of induced abortion. *BCMJ* 2002;44:367–373.
2. Miller L, Thomas K, Hughes JP, Holmes KK, Stout S, Eschenbach DA. Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication. *BJOG* 2004;111:982–988.
3. *Guidance on the Processing and Distribution of Semen for Assisted Conception Regulations*. Ottawa, ON: Health Products and Food Branch, Health Canada; 2004.
4. Witkin SS, Linhares IM. Chlamydia trachomatis in subfertile women undergoing uterine instrumentation: an alternative to direct microbial testing or prophylactic antibiotic treatment. *Hum Reprod* 2002;17:1938–1941.
5. Sowerby E, Parsons J. Prevention of iatrogenic pelvic infection during in vitro fertilization — current practice in the UK. *Hum Fertil (Camb)* 2004;7:135–140.
6. Monif GRG, Baker DA. *Infectious Diseases in Obstetrics and Gynecology*. 5th ed. New York, NY: Parthenon Publishing; 2004: 323–324.
7. Johnson RE, Newhall WJ, Papp JR, et al. Screening to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections—2002. *MMWR Recomm Rep* 2002;51(RR-15):1–38.
8. Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E. Prospective study of perinatal transmission of Chlamydia trachomatis. *JAMA* 1986;255:3374–3377.
9. Alary M, Joly JR, Moutquin JM, et al. Randomized comparison of amoxicillin and erythromycin in treatment of genital chlamydial infection in pregnancy. *Lancet* 1994;344:1461–1465
10. Brocklehurst P, Rooney G. Interventions for treating genital Chlamydia trachomatis infections in pregnancy. *Cochrane Database Syst Rev* 2000;2:CD000054.
11. Adair CD, Gunter M, Stovall TG, McElvoy G, Veille JC, Ernest JM. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. *Obstet Gynecol* 1998;91:165–168.
12. Wehbeh HA, Ruggierio RM, Shakem S, Lopez G, Ali Y. Single dose azithromycin for Chlamydia in pregnant women. *J Reprod Med* 1998;43:509–514.
13. Takahashi S, Hagiwara T, Shiga S, Hirose T, Tsukamoto T. Detection of antimicrobial-treated Chlamydia trachomatis with Amplicor PCR test kit. *J Infect Chemother* 2000;6:211–215.
14. Brocklehurst P. Antibiotics for gonorrhoeae in pregnancy. *Cochrane Database Syst Rev* 2002;2:CD000098.
15. Ramus RM, Sheffield JS, Mayfield JA, Wendel GD Jr. A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. *Am J Obstet Gynecol* 2001;185:629–632.
16. Kouri YH, Gonzalez L, Perez M, et al. Effect of penicillin and spectinomycin given for urethritis and cervicitis with Neisseria gonorrhoeae: high prevalence of penicillin-resistant isolates. *Genitourin Med* 1989;65:342–346.
17. Creighton S, Tenant-Flowers M, Taylor CB, Miller R, Low N. Co-infection with gonorrhea and chlamydia: how much is there and what does it mean? *Int J STD AIDS* 2003;14:109–113.
18. Washington AE, Browner WS, Korenbrot CC. Cost-effectiveness of combined treatment for endocervical gonorrhea. Considering co-infection with chlamydia trachomatis. *JAMA* 1987;257:2056–2060.

19. Fiumara NJ, Fleming WL, Downing JG, Good FL. The incidence of prenatal syphilis at the Boston City Hospital. *N Engl J Med* 1952;247:48–52.
20. Alexander JM, Sheffield JS, Sanchez PJ, Mayfield J, Wendel GD Jr. Efficacy of treatment for syphilis in pregnancy. *Obstet Gynecol* 1999;93:5–8.
21. Jones H, Taylor D, Montgomery CA, et al. Prenatal and congenital syphilis in British Columbia. *J Obstet Gynaecol Can* 2005;27:467–472.
22. Walker GJ. Antibiotics for syphilis diagnosed during pregnancy. *Cochrane Library* 2002:3.
23. Peter G, Dudley MN. Clinical pharmacology of benzathine penicillin. *Pediatr Infect Dis* 1985;4:586-91.
24. Genc M, Ledger WJ. Syphilis in pregnancy. *Sex Transm Infect* 2000;76:73–79.
25. Wendel GD Jr, Sheffield JS, Hollier LM, Hill JB, Ramsey PS, Sanchez PJ. Treatment of syphilis in pregnancy and prevention of congenital syphilis. *Clin Infect Dis* 2002;35(suppl 2):S200–209.
26. Myles TD, Elam G, Park-Hwang E, Nguyen T. The Jarisch-Herxheimer reaction and fetal monitoring changes in pregnant women treated for syphilis. *Obstet Gynecol* 1998;92:859–864.
27. Klebanoff MA, Carey JC, Hauth JC, et al; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic *Trichomonas vaginalis* infection. *N Engl J Med* 2001;345:487–493.
28. duBouchet L, McGregor JA, Ismail M, McCormack WM. A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of *Trichomonas vaginalis* vaginitis. *Sex Transm Dis* 1998;25:176–179.
29. Tidwell BH, Lushbaugh WB, Laughlin MD, Cleary JD, Finley RW. A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis. *J Infect Dis* 1994;170:242–246.
30. Hager WD, Brown ST, Kraus SJ, Kleris GS, Perkins GJ, Henderson M. Metronidazole for vaginal trichomoniasis. Seven-day vs single-dose regimens. *JAMA* 1980;244:1219–1220.
31. Caro-Paton T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodriguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. *Br J Clin Pharmacol* 1997;44:179–182.
32. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. *Am J Obstet Gynecol* 1995;172(2 Pt 1):525–529.
33. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. *Obstet Gynecol* 1993;82:348–352.
34. Antonelli NM, Diehl SJ, Wright JW. A randomized trial of intravaginal nonoxynol 9 versus oral metronidazole in the treatment of vaginal trichomoniasis. *Am J Obstet Gynecol* 2000;182:1008–1010.
35. Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. *N Engl J Med* 1995;333:1732–1736.
36. Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. *Am J Obstet Gynecol* 1994;171:345–347.
37. McDonald HM, O’Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (*Gardnerella vaginalis*): a randomised, placebo controlled trial. *Br J Obstet Gynaecol* 1997;104:1391–1397.
38. McDonald H, Brockelhurst P, Parsons J, Vigneswaran R. Antibiotics for treating bacterial vaginosis in pregnancy. *Cochrane Database Syst Rev* 2003;2:CD000262.
39. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. *N Engl J Med* 2000;342:534–540.
40. McGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results from a controlled trial of topical clindamycin cream. *Am J Obstet Gynecol* 1994;170:1048–1059.

41. Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. *Am J Obstet Gynecol* 1995;173:1527–1531.
42. Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. *Br J Obstet Gynaecol* 1999;106:652–657.
43. Young GL, Jewell D. Topical treatment for vaginal (thrush) in pregnancy. *Cochrane Database Syst Rev* 2001;4:CD000225.
44. Menegola E, Broccia ML, DiRenzo F, Giavini E. Antifungal triazoles induce malformations in vitro. *Reprod Toxicol* 2001;15:421–427.
45. Mastoiacovo P, Mazzone T, Botto LD, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. *Am J Obstet Gynecol* 1996;175:1645–1650.
46. Aleck XA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. *Am J Med Genet* 1997;72:253–256.
47. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. *Clin Infect Dis* 1996;22:336–340.
48. Chapin RE and Ku WW. The reproductive toxicity of boric acid. *Environ Health Perspect* 1994;102(suppl 7):87–91.
49. Hart G. Factors associated with pediculosis pubis and scabies. *Genitourin Med* 1992;68:294–295.
50. Scott GR. European guideline for the management of scabies. *Int J STD AIDS* 2001;12(suppl 3):58–61.
51. Hollier LM, Workowski K. Treatment of sexually transmitted diseases in women. *Obstet Gynecol Clin North Am* 2003;30:751–775.
52. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labour. *N Engl J Med* 1991;324:1247–1252.
53. Prober CG, Corey L, Brown ZA, et al. The management of pregnancies complicated by genital infections with herpes simplex virus. *Clin Infect Dis* 1992;15:1031–1038.
54. Whitley RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates. *J Infect Dis* 1988;158:109–116.
55. Kropp RY, Wong T, Burton S, Embree J, Steben M. Neonatal herpes simplex virus infections in Canada; Valacyclovir HSV Transmission Study Group. *Int J STD AIDS* 2004;15(suppl 1):2.
56. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. *N Engl J Med* 2004;350:11–20.
57. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. *Am J Obstet Gynecol* 2003;188:836–843.
58. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. *JAMA* 2003;289:203–209.
59. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. *N Engl J Med* 1984;310:1551–1556.
60. Strauss SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. *N Engl J Med* 1984;310:1545–1550.
61. Sheffield JS, Hill JB, Mollier LM, Laibl VR, Roberts SW, Schez PJ and Wendel Jr. GD. Valacyclovir prophylaxis to prevent herpes at delivery. *Am J Obstet Gynecol* 2006; 180:141-147
62. Sheffield JS, Hooler LM, Hill JB, Stuart GS, Wendel GD. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. *Obstet Gynecol* 2003;102:1396–1403.
63. Amstey MS, Monif GR. Genital herpesvirus infection in pregnancy. *Obstet Gynecol* 1974;44:394–397.
64. Nahmias AJ, Josey WE, Naib ZM, Freeman MG, Fernandez RJ, Wheeler JH. Perinatal risk associated with maternal genital herpes simplex virus infection. *Am J Obstet Gynecol* 1971;110:825–837.

65. Smith EM, Ritchie JM, Yankowitz J, et al. Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission. *Sex Transm Dis* 2004;31:57–62.
66. Armstrong LR, Preston EJ, Reichert M, et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. *Clin Infect Dis* 2000;31:107–109.
67. Watts DH, Koutsky LA, Holmes KK, et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. *Am J Obstet Gynecol* 1998;178:365–373.
68. Gall SA. Maternal immunization. *Obstet Gynecol Clin North Am* 2003;30:623–636.
69. Sweet RL. Hepatitis B infection in pregnancy. *Obstet Gynecol Rep* 1990;2:128–139.
70. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. *Lancet* 1989;1:406–410.
71. *Canadian Immunization Guide*. 7th ed. Ottawa, ON. Public Health Agency of Canada; 2006.
72. Hepatitis C — prevention and control: a public health consensus. Ottawa, Canada, October 14–16, 1998. *Can Commun Dis Rep* 1999;25(suppl 2):1–22.
73. Locatelli A, Roncaglia N, Arreghini A, Bellini P, Vergani P, Ghidini A. Hepatitis C virus infection is associated with a higher incidence of cholestasis of pregnancy. *Br J Obstet Gynaecol* 1999;106:498–500.
74. Boucher M, Gruslin A, Delage G, et al. The reproductive care of women living with hepatitis C infection. *J SOGC* 2000;96:4–29.
75. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. *BJOG* 2001;108:371–377.
76. Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. *J Hepatol* 1998;29:191–197.
77. Hiratsuka M, Minakami H, Koshizuka S, Sato I. Administration of interferon-alpha during pregnancy: effects on fetus. *J Perinat Med* 2000;28:372–376.
78. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. *JAMA* 1990;264:2231–2235.
79. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. *JAMA* 1989;262:1201–1205.
80. Dienstag JL. Sexual and perinatal transmission of hepatitis C. *Hepatology* 1997;26(3 suppl 1):66S–70S.
81. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. *Drug Saf* 1994;10:281–291.
82. Burdge D, Money DM, Forbes JC; Canadian HIV Trials Network Working Group on Vertical HIV Transmission. Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines). *CMAJ* 2003;168:1671–1674.
83. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. *JAMA* 1998;280:55–60.
84. Kind C, Rudin C, Siegrist CA, et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. *AIDS* 1998;12:205–210.
85. European Mode of Delivery Collaboration. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. *Lancet* 1999;353:1035–1039.
86. The International Perinatal HIV Group. The mode of delivery and vertical transmission of human immunodeficiency virus type 1 — a meta-analysis of 15 prospective cohort studies. *N Engl J Med* 1999;340:977–987.
87. Boucher M, Cohen HR, Gruslin A, Money DM, Steben M, Wong T. Mode of delivery for pregnant women infected by the human immunodeficiency virus. *J SOGC* 2001;101:1–3.